MayMag Biologics formerly Tirzepatide Pharma Biopharmaceutical Compounding Industry For FDA Approved Sterile 506e Biologics

 Company Description

MayMag Biologics is a Dallas, Texas-based FDA-registered 506(e) outsourcing facility and full-service contract development and manufacturing organization (CDMO) specializing in peptide API synthesis, sterile injectable compounding, biosimilar drug manufacturing, bacteriostatic water for injection (BWFI), and auto-injection device production.

 

As a registered 506(e) outsourcing facility under the Drug Quality and Security Act (DQSA), MayMag Biologics operates under direct FDA oversight — distinct from traditional state-regulated compounding pharmacies. This designation enables large-scale sterile drug manufacturing for commercial distributors, hospital systems, and pharmaceutical sponsors nationwide.

Core Manufacturing Capabilities

Insulin fill-finish 70/30, Glargine, Epinephrine pens and Peptide API Synthesis MayMag Biologics performs solid-phase peptide synthesis (SPPS) for GLP-1 agonists including tirzepatide, semaglutide analogs, and custom peptide sequences at clinical and commercial scale. Our peptide manufacturing capabilities serve pharmaceutical sponsors seeking a domestic U.S. alternative to offshore API suppliers.

 

Biosimilar Drug Manufacturing Our biosimilar CDMO services include compounded formulations of insulin analogs, GLP-1/GIP dual agonists, and anti-inflammatory biologics. We manufacture biosimilar products addressing critical national drug shortages under FDA 506(e) outsourcing facility designation.

 

Sterile Injectable Manufacturing MayMag Biologics provides fill-finish manufacturing for sterile injectables including prefilled syringes, multi-dose vials, and lyophilized drug products. All sterile manufacturing operations comply with USP Chapter 797 and 800 standards and 21 CFR Parts 210–211.

 

Bacteriostatic Water for Injection (BWFI) We manufacture bacteriostatic water for injection (BWFI) in multi-dose vials for use as a diluent in peptide and protein drug reconstitution. BWFI production operates under full cGMP compliance and USP sterility standards.

 

Auto-Injection Device Manufacturing MayMag Biologics manufactures epinephrine auto-injectors (EpiPen-equivalent), insulin pens, and rheumatoid arthritis autoinjectors. Our automated auto-injection pen manufacturing line addresses critical domestic supply chain gaps for life-saving emergency medications.

 

Inhalation Therapeutics Our inhalation drug product capabilities include metered-dose inhaler (MDI) and dry powder inhaler (DPI) formulation development and fill-finish manufacturing for respiratory therapeutics.

 

Regulatory Credentials

  • FDA-registered 506(e) outsourcing facility (DQSA)
  • cGMP compliant — 21 CFR Parts 210–211
  • GMP Certified
  • ISO 13485 certified
  • USP Chapter 797 compliant (sterile compounding)
  • USP Chapter 800 compliant (hazardous drug handling)

Facilities: MayMag Biologics operates dual cGMP-certified facilities in the Dallas–Fort Worth metroplex:

  • Dallas, Texas — Primary sterile manufacturing and fill-finish operations
  • Garland, Texas — Peptide API synthesis, quality control, and analytical testing

Both facilities are FDA-inspected and operate under continuous quality management systems with full batch record documentation, environmental monitoring, and third-party audit readiness.

Why MayMag Biologics: The U.S. pharmaceutical industry's dependence on overseas API supply chains has created significant risk for patients, sponsors, and healthcare systems. MayMag Biologics was founded to provide a fully domestic, FDA-inspected alternative — combining the regulatory rigor of a 506(e) outsourcing facility with the agility and responsiveness of a specialized CDMO.

 Partnership & RFQ Inquiries Visit tirzepatidepharm.com/contact or email cdmo@tirzepatidepharm.com

Field

Value

Careers Page URL

https://tirzepatidepharm.com/careers

Open Positions

Quality Control Analyst, Regulatory Affairs Specialist

Job Categories

Pharmaceutical Manufacturing, Biotechnology, Quality Assurance, R&D

Location

Dallas, TX and Garland, TX

 

Job Positions:

  1. Quality Control Analyst — Dallas, TX
  2. Peptide Synthesis Scientist — Garland, TX
  3. Regulatory Affairs Specialist — Dallas, TX

Keywords / Tags

506e outsourcing facility, peptide API manufacturer, CDMO, tirzepatide manufacturer, semaglutide, GLP-1 manufacturer, biosimilar CDMO, sterile injectable manufacturer, bacteriostatic water, BWFI, epinephrine auto-injector, insulin pen manufacturer, cGMP contract manufacturer, Dallas Texas pharmaceutical, domestic API manufacturer, 506(e) registration, drug shortage manufacturer, GLP-1 GIP dual agonist

Platform

URL

Website

https://tirzepatidepharm.com

Press Room

https://tirzepatidepharm.com/press

Media Kit

https://tirzepatidepharm.com/media-kit

Blog

https://tirzepatidepharm.com/blog

Facebook

https://www.facebook.com/284491162424541

Comments

Popular posts from this blog

MayMag Biologics Corp Expands Domestic cGMP Co-Manufacturing Capacity in Texas to Support SAM.gov Federal Prime Contractors

Scalable industrial 506e offering high-volume pharmaceutical large-scale prescription manufacturing.